Pharma BD Deal Intelligence

Astra AB / Zeneca Group plc

1998 · Acquisition/Merger · $35.0B · Complete

Announcement Sentiment

Skeptical

Outcome Score

Worked — the deal delivered on its rationale.

Astra AB and Zeneca Group plc merged in a ~$35 billion all-share merger of equals to create AstraZeneca, the world's third-largest pharmaceutical company by sales. Zeneca shareholders received 53.5% and Astra shareholders 46.5% of the combined entity. The deal was completed in just 80 days.

Key facts

Announced Dec 09, 1998
Closed Apr 06, 1999
Deal value $35.0B
Deal type Acquisition/Merger
Therapeutic area Cardiovascular, Gastroenterology, Neurology, Oncology, Respiratory
Indications Acid Reflux/GERD, Breast Cancer, Hypertension
Key assets Losec/Prilosec (omeprazole), Nolvadex (tamoxifen), Arimidex (anastrozole), Atacand (candesartan), Zoladex (goserelin)
Mechanism Proton pump inhibitor, Selective estrogen receptor modulator, Aromatase inhibitor

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals